Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN10018 + tislelizumab + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- InxMed
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A four-drug combination therapy consisting of **IN10018** (a selective FAK inhibitor), **tislelizumab** (a humanized anti–PD-1 IgG4 monoclonal antibody), **carboplatin** (a platinum-based DNA crosslinker), and **etoposide** (a topoisomerase II inhibitor). This regimen is currently under phase Ib/II clinical investigation as a first-line treatment in adults with **extensive-stage small cell lung cancer (ES-SCLC)**. The combination leverages multiple mechanisms: immune checkpoint inhibition (PD-1 blockade by tislelizumab), disruption of tumor stroma and enhancement of immune infiltration (by IN10018), and direct cytotoxicity against tumor cells (by carboplatin and etoposide). The combination is designed to maximize anti-tumor efficacy through synergy between immunotherapy, targeted therapy, and cytotoxic chemotherapy[1][4][5][7].
- Other names
- BI 853520BI853520BI-853520BGB-A317BGB-A-317BGB-A 317Baizean
02
Targets
TOP2A (DNA topoisomerase II)DNAFAK (Focal adhesion kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on IN10018 + tislelizumab + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN10018 + tislelizumab + carboplatin + etoposide.